EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Antibody-Drug Conjugates in Bladder Cancer

Panagiotis J Vlachostergios, Christopher D Jakubowski, Muhammad J Niaz, Aileen Lee, Charlene Thomas, Amy L Hackett, Priyanka Patel, Naureen Rashid, Scott T Tagawa

Bladder Cancer · 17.07.2018 · 4 (3) · 247-259

DOI: 10.3233/blc-180169 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bladder Cancer, online erschienen am 11.07.2018. Verfasst von Panagiotis J Vlachostergios und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific target and a cytotoxic drug connected via a linker molecule. Several ADCs are developed against different UC surface markers, but the ones at most advanced stages of development include sacituzumab govitecan (IMMU-132), enfortumab vedotin (ASG-22CE/ASG-22ME), ASG-15ME for advanced UC, and oportuzumab monatox (VB4-845) for early UC. Several new targets are identified and utilized for novel or existing ADC testing. The most promising ones include human epidermal growth factor receptor 2 (HER2) and members of the fibroblast growth factor receptor axis (FGF/FGFR). Positive preclinical and early clinical results are reported in many cases, thus the next step involves further improving efficacy and reducing toxicity as well as testing combination strategies with approved agents.

Schlagwörter

Stichwörter der Autor:innen

Antibody-drug conjugatebladder cancertargeted therapyurothelial carcinoma

Autor:innen und Institutionen

  • Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
  • Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Department of Urology, Weill Cornell Medicine, New York, NY, USA.

Zitieren

APA

Vlachostergios, P. J., Jakubowski, C. D., Niaz, M. J., Lee, A., Thomas, C., Hackett, A. L., Patel, P., Rashid, N., & Tagawa, S. T. (2018). Antibody-Drug Conjugates in Bladder Cancer. Bladder Cancer, 4(3), 247-259. https://doi.org/10.3233/blc-180169

Vancouver

Vlachostergios PJ, Jakubowski CD, Niaz MJ, Lee A, Thomas C, Hackett AL, et al. Antibody-Drug Conjugates in Bladder Cancer. Bladder Cancer. 2018;4(3):247-259. doi:10.3233/blc-180169

BibTeX
@article{Vlachostergios2018,
  author = {Vlachostergios, Panagiotis J and Jakubowski, Christopher D and Niaz, Muhammad J and Lee, Aileen and Thomas, Charlene and Hackett, Amy L and Patel, Priyanka and Rashid, Naureen and Tagawa, Scott T},
  title = {Antibody-Drug Conjugates in Bladder Cancer},
  journal = {Bladder Cancer},
  year = {2018},
  volume = {4},
  number = {3},
  pages = {247--259},
  doi = {10.3233/blc-180169}
}
Kostenlos starten →